Benjamin A. Gartrell

4.3k citations

74 papers · 1.4k indexed · 1 hit paper · h-index 17

Impact in

Oncology top 5%
- COVID-19 and healthcare impacts
- Bone health and treatments
Pulmonary and Respiratory Medicine top 5%
- Prostate Cancer Treatment and Research
- Renal cell carcinoma treatment

Papers in ⓘ

Pulmonary and Respiratory Medicine 50
- Prostate Cancer Treatment and Research 27
- Renal cell carcinoma treatment 19
Oncology 34
- Cancer Immunotherapy and Biomarkers 14
- Bone health and treatments 7

Co-authors: Fred Saad (8 shared papers)Matthew D. Galsky (11 shared papers)Guru Sonpavde (14 shared papers)Sanjay Goel (5 shared papers)Kith Pradhan (3 shared papers)Amit Verma (3 shared papers)Ana Acuña-Villaorduña (1 shared paper)Daniel J. Cole (1 shared paper)
Journals: Journal of Clinical Oncology (28 papers)European Urology Oncology (4 papers)Urologic Oncology Seminars and Original Investigations (4 papers)Clinical Genitourinary Cancer (3 papers)Annals of Oncology (3 papers)
Partner nations: United States United Kingdom Canada

In The Last Decade

Benjamin A. Gartrell

71 papers receiving 1.4k citations

Hit Papers

align trajectories log scale

Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System 2020 · 521 citations

Peers

Countries citing papers authored by Benjamin A. Gartrell

Since Specialization

Citations

This map shows the geographic impact of Benjamin A. Gartrell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin A. Gartrell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin A. Gartrell more than expected).

Fields of papers citing papers by Benjamin A. Gartrell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Benjamin A. Gartrell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin A. Gartrell. The network helps show where Benjamin A. Gartrell may publish in the future.

Co-authors

The 25 scholars most cited alongside Benjamin A. Gartrell, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Benjamin A. Gartrell Line = papers co-authored together Benjamin A. Gartrell links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 74 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System Cancer Discovery ·Vikas Mehta, Sanjay Goel, Rafi Kabarriti, Daniel J. Cole, Mendel Goldfinger, Ana Acuña-Villaorduña, Kith Pradhan, Raja Thota, Stan Reissman, Joseph A. Sparano, Benjamin A. Gartrell, Richard V. Smith, Nitin Ohri, Madhur Garg, Andrew D. Racine, Shalom Kalnicki, Román Pérez-Soler, Balázs Halmos, Amit Verma Hit paper breakdown →	2020	521
2	Managing bone metastases and reducing skeletal related events in prostate cancer Nature Reviews Clinical Oncology ·Benjamin A. Gartrell, Fred Saad	2014	96
3	Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options European Urology ·Benjamin A. Gartrell, Robert E. Coleman, Eleni Efstathiou, Karim Fizazi, Christopher J. Logothetis, Matthew R. Smith, Guru Sonpavde, Oliver Sartor, Fred Saad	2015	69
4	Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer Journal of Clinical Oncology ·Alicia K. Morgans, Yu‐Hui Chen, Christopher J. Sweeney, David F. Jarrard, Elizabeth R. Plimack, Benjamin A. Gartrell, Michael A. Carducci, Maha Hussain, Jorge A. García, David Cella, Robert S. DiPaola, Linda Patrick‐Miller	2018	66
5	Metabolic complications with the use of mTOR inhibitors for cancer therapy Cancer Treatment Reviews ·Shanthi Sivendran, Neeraj Agarwal, Benjamin A. Gartrell, Jian Ying, Kenneth M. Boucher, Toni K. Choueiri, Guru Sonpavde, William Oh, Matthew D. Galsky	2013	60
6	Functional succinate dehydrogenase deficiency is a common adverse feature of clear cell renal cancer Proceedings of the National Academy of Sciences ·Ritesh K. Aggarwal, Rebecca A. Luchtel, Venkata R. Machha, Alexander Tischer, Yiyu Zou, Kith Pradhan, Nadia Ashai, Nandini Ramachandra, Joseph Albanese, Jung‐In Yang, Xiaoyang Wang, Srinivas Aluri, Shanisha Gordon, Ahmed Aboumohamed, Benjamin A. Gartrell, Sassan Hafizi, James Pullman, Niraj Shenoy	2021	52
7	Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis World Journal of Urology ·Che-Kai Tsao, Alexander Small, Max Kates, Erin Moshier, Juan P. Wisnivesky, Benjamin A. Gartrell, Guru Sonpavde, James Godbold, Michael Palese, Simon J. Hall, William Oh, Matthew D. Galsky	2012	49
8	Prevalence and characteristics of patients with metastatic cancer who receive no anticancer therapy Cancer ·Alexander Small, Che‐Kai Tsao, Erin Moshier, Benjamin A. Gartrell, Juan P. Wisnivesky, James Godbold, Cardinale B. Smith, Guru Sonpavde, William Oh, Matthew D. Galsky	2012	41
9	Distinctive mechanisms underlie the loss of SMARCB1 protein expression in renal medullary carcinoma: morphologic and molecular analysis of 20 cases Modern Pathology ·Liwei Jia, Maria I. Carlo, Hina Khan, Gouri J. Nanjangud, Satshil Rana, Robert Cimera, Yanming Zhang, A. Ari Hakimi, Amit Verma, Hikmat Al‐Ahmadie, Samson W. Fine, Anuradha Gopalan, S. Joseph Sirintrapun, Satish K. Tickoo, Victor E. Reuter, Benjamin A. Gartrell, Ying‐Bei Chen	2019	39
10	Toxicities Following Treatment with Bisphosphonates and Receptor Activator of Nuclear Factor-κB Ligand Inhibitors in Patients with Advanced Prostate Cancer European Urology ·Benjamin A. Gartrell, Robert E. Coleman, Karim Fizazi, Kurt Miller, Fred Saad, Cora N. Sternberg, Matthew D. Galsky	2013	34
11	Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy Therapeutic Advances in Urology ·Benjamin A. Gartrell, Fred Saad	2015	29
12	Immune evasion in renal cell carcinoma: biology, clinical translation, future directions Kidney International ·Xiaoyang Wang, Robert Lopez, Rebecca A. Luchtel, Sassan Hafizi, Benjamin A. Gartrell, Niraj Shenoy	2020	26
13	The follicle-stimulating hormone receptor: A novel target in genitourinary malignancies Urologic Oncology Seminars and Original Investigations ·Benjamin A. Gartrell, Che-Kai Tsao, Matthew D. Galsky	2012	25
14	A Phase 1b/2 Study of Atezolizumab with or Without Bacille Calmette-Guérin in Patients with High-risk Non–muscle-invasive Bladder Cancer European Urology Oncology ·Brant A. Inman, Noah M. Hahn, Kelly Stratton, Ryan Kopp, Alex Sankin, Eila C. Skinner, Kamal S. Pohar, Benjamin A. Gartrell, Song Pham, Deepali Rishipathak, Sanjeev Mariathasan, Nicole N. Davarpanah, Corey Carter, Gary D. Steinberg	2023	21
15	Trends in the Use of Cytoreductive Nephrectomy in the United States Clinical Genitourinary Cancer ·Che-Kai Tsao, Alexander Small, Erin Moshier, Benjamin A. Gartrell, Juan P. Wisnivesky, Guru Sonpavde, James Godbold, Michael Palese, Simon J. Hall, William Oh, Matthew D. Galsky	2012	20
16	Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis Targeted Oncology ·Benjamin A. Gartrell, Jian Ying, Shanthi Sivendran, Kenneth M. Boucher, Toni K. Choueiri, Guru Sonpavde, William Oh, Neeraj Agarwal, Matthew D. Galsky	2013	20
17	Impressive and durable response to nivolumab in a patient with metastatic type 2 papillary renal cell carcinoma: On-label but without evidence Investigational New Drugs ·Diego Adrianzen Herrera, Sarah B. Fleisig, Benjamin A. Gartrell	2017	18
18	Trends and variations in utilization of nephron-sparing procedures for stage I kidney cancer in the United States World Journal of Urology ·Alexander Small, Che-Kai Tsao, Erin Moshier, Benjamin A. Gartrell, Juan P. Wisnivesky, James Godbold, Guru Sonpavde, Michael Palese, Simon J. Hall, William Oh, Matthew D. Galsky	2012	15
19	PrE0807: A phase Ib feasibility trial of neoadjuvant nivolumab (N) without or with lirilumab (L) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC). Journal of Clinical Oncology ·Petros Grivas, Jun Yin, Vadim S. Koshkin, Suzanne Cole, Rohit Jain, Robert Dreicer, Jeremy Cetnar, Debasish Sundi, Benjamin A. Gartrell, Matt D. Galsky, Colin M Sievers, Noah M. Hahn, Michael A. Carducci	2021	15
20	PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant Chemotherapy European Urology Oncology ·Petros Grivas, Vadim S. Koshkin, Xiangying Chu, Suzanne Cole, Rohit Jain, Robert Dreicer, Jeremy Cetnar, Debasish Sundi, Benjamin A. Gartrell, Matthew D. Galsky, Brianna Woo, Elsa M. Li-Ning-Tapia, Noah M. Hahn, Michael A. Carducci	2023	13

About Benjamin A. Gartrell

Benjamin A. Gartrell is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Surgery, Cancer Research and Radiology, Nuclear Medicine and Imaging, having authored 74 papers that have together received 1.4k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (27 papers), Bladder and Urothelial Cancer Treatments (23 papers), Renal cell carcinoma treatment (19 papers), Cancer Immunotherapy and Biomarkers (14 papers), Urinary and Genital Oncology Studies (11 papers), Radiopharmaceutical Chemistry and Applications (11 papers), Renal and related cancers (7 papers) and Bone health and treatments (7 papers). The work is most often cited by research in Oncology (823 citations), Pulmonary and Respiratory Medicine (586 citations), Infectious Diseases (322 citations), Cancer Research (161 citations) and Radiology, Nuclear Medicine and Imaging (193 citations). Benjamin A. Gartrell has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Fred Saad, Matthew D. Galsky, Guru Sonpavde, Sanjay Goel, Kith Pradhan, Amit Verma, Ana Acuña-Villaorduña, Daniel J. Cole, Raja Thota and Mendel Goldfinger. Their work appears in journals such as Journal of Clinical Oncology, European Urology Oncology, Urologic Oncology Seminars and Original Investigations, Clinical Genitourinary Cancer and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact